Edgar Tapia1, Diana Evelyn Villa-Guillen2, Pavani Chalasani1,3, Sara Centuori1,3, Denise J Roe1,4, Jose Guillen-Rodriguez1, Chuan Huang5, Jean-Phillippe Galons1,6, Cynthia A Thomson1,7, Maria Altbach1,6, Jesse Trujillo1, Liane Pinto1, Jessica A Martinez1,8, Amit M Algotar1,9, H-H Sherry Chow10,11. 1. University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA. 2. Department of Biological-Chemistry Sciences, University of Sonora, Hermosillo, Sonora, Mexico. 3. Department of Medicine, University of Arizona, Tucson, AZ, USA. 4. Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA. 5. Department of Radiology, Stony Brook University, Stony Brook, NY, USA. 6. Department of Medical Imaging, University of Arizona, Tucson, AZ, USA. 7. Department of Health Promotion Sciences, University of Arizona, Tucson, AZ, USA. 8. Department of Nutritional Sciences, University of Arizona, Tucson, AZ, USA. 9. Department of Family and Community Medicine, University of Arizona, Tucson, AZ, USA. 10. University of Arizona Cancer Center, University of Arizona, 1515 N Campbell Ave, Tucson, AZ, 85724, USA. schow@azcc.arizona.edu. 11. Department of Medicine, University of Arizona, Tucson, AZ, USA. schow@azcc.arizona.edu.
Abstract
PURPOSE: Obesity is a known risk factor for post-menopausal breast cancer and may increase risk for triple negative breast cancer in premenopausal women. Intervention strategies are clearly needed to reduce obesity-associated breast cancer risk. METHODS: We conducted a Phase II double-blind, randomized, placebo-controlled trial of metformin in overweight/obese premenopausal women with components of metabolic syndrome to assess the potential of metformin for primary breast cancer prevention. Eligible participants were randomized to receive metformin (850 mg BID, n = 76) or placebo (n = 75) for 12 months. Outcomes included breast density, assessed by fat/water MRI with change in percent breast density as the primary endpoint, anthropometric measures, and intervention feasibility. RESULTS: Seventy-six percent in the metformin arm and 83% in the placebo arm (p = 0.182) completed the 12-month intervention. Adherence to study agent was high with more than 80% of participants taking ≥ 80% assigned pills. The most common adverse events reported in the metformin arm were gastrointestinal in nature and subsided over time. Compared to placebo, metformin intervention led to a significant reduction in waist circumference (p < 0.001) and waist-to-hip ratio (p = 0.019). Compared to placebo, metformin did not change percent breast density and dense breast volume but led to a numerical but not significant decrease in non-dense breast volume (p = 0.070). CONCLUSION: We conclude that metformin intervention resulted in favorable changes in anthropometric measures of adiposity and a borderline decrease in non-dense breast volume in women with metabolic dysregulation. More research is needed to understand the impact of metformin on breast cancer risk reduction. TRIAL REGISTRATION: ClinicalTrials.gov NCT02028221. Registered January 7, 2014, https://clinicaltrials.gov/ct2/show/NCT02028221.
PURPOSE: Obesity is a known risk factor for post-menopausal breast cancer and may increase risk for triple negative breast cancer in premenopausal women. Intervention strategies are clearly needed to reduce obesity-associated breast cancer risk. METHODS: We conducted a Phase II double-blind, randomized, placebo-controlled trial of metformin in overweight/obese premenopausal women with components of metabolic syndrome to assess the potential of metformin for primary breast cancer prevention. Eligible participants were randomized to receive metformin (850 mg BID, n = 76) or placebo (n = 75) for 12 months. Outcomes included breast density, assessed by fat/water MRI with change in percent breast density as the primary endpoint, anthropometric measures, and intervention feasibility. RESULTS: Seventy-six percent in the metformin arm and 83% in the placebo arm (p = 0.182) completed the 12-month intervention. Adherence to study agent was high with more than 80% of participants taking ≥ 80% assigned pills. The most common adverse events reported in the metformin arm were gastrointestinal in nature and subsided over time. Compared to placebo, metformin intervention led to a significant reduction in waist circumference (p < 0.001) and waist-to-hip ratio (p = 0.019). Compared to placebo, metformin did not change percent breast density and dense breast volume but led to a numerical but not significant decrease in non-dense breast volume (p = 0.070). CONCLUSION: We conclude that metformin intervention resulted in favorable changes in anthropometric measures of adiposity and a borderline decrease in non-dense breast volume in women with metabolic dysregulation. More research is needed to understand the impact of metformin on breast cancer risk reduction. TRIAL REGISTRATION: ClinicalTrials.gov NCT02028221. Registered January 7, 2014, https://clinicaltrials.gov/ct2/show/NCT02028221.
Authors: P A van den Brandt; D Spiegelman; S S Yaun; H O Adami; L Beeson; A R Folsom; G Fraser; R A Goldbohm; S Graham; L Kushi; J R Marshall; A B Miller; T Rohan; S A Smith-Warner; F E Speizer; W C Willett; A Wolk; D J Hunter Journal: Am J Epidemiol Date: 2000-09-15 Impact factor: 4.897
Authors: Jack A Yanovski; Jonathan Krakoff; Christine G Salaita; Jennifer R McDuffie; Merel Kozlosky; Nancy G Sebring; James C Reynolds; Sheila M Brady; Karim A Calis Journal: Diabetes Date: 2011-01-12 Impact factor: 9.461
Authors: Cynthia A Thomson; H H Sherry Chow; Betsy C Wertheim; Denise J Roe; Alison Stopeck; Gertraud Maskarinec; Maria Altbach; Pavani Chalasani; Chuan Huang; Meghan B Strom; Jean-Philippe Galons; Patricia A Thompson Journal: Breast Cancer Res Treat Date: 2017-05-30 Impact factor: 4.872
Authors: Norman Boyd; Lisa Martin; Anoma Gunasekara; Olga Melnichouk; Gord Maudsley; Chris Peressotti; Martin Yaffe; Salomon Minkin Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-06 Impact factor: 4.254
Authors: Kotha Subbaramaiah; Louise R Howe; Priya Bhardwaj; Baoheng Du; Claudia Gravaghi; Rhonda K Yantiss; Xi Kathy Zhou; Victoria A Blaho; Timothy Hla; Peiying Yang; Levy Kopelovich; Clifford A Hudis; Andrew J Dannenberg Journal: Cancer Prev Res (Phila) Date: 2011-03
Authors: Andreas Pettersson; Rebecca E Graff; Giske Ursin; Isabel Dos Santos Silva; Valerie McCormack; Laura Baglietto; Celine Vachon; Marije F Bakker; Graham G Giles; Kee Seng Chia; Kamila Czene; Louise Eriksson; Per Hall; Mikael Hartman; Ruth M L Warren; Greg Hislop; Anna M Chiarelli; John L Hopper; Kavitha Krishnan; Jingmei Li; Qing Li; Ian Pagano; Bernard A Rosner; Chia Siong Wong; Christopher Scott; Jennifer Stone; Gertraud Maskarinec; Norman F Boyd; Carla H van Gils; Rulla M Tamimi Journal: J Natl Cancer Inst Date: 2014-05-10 Impact factor: 13.506
Authors: Adam R Brentnall; Ruth Warren; Elaine F Harkness; Susan M Astley; Julia Wiseman; Jill Fox; Lynne Fox; Mikael Eriksson; Per Hall; Jack Cuzick; D Gareth Evans; Anthony Howell Journal: Breast Cancer Res Date: 2020-09-29 Impact factor: 6.466
Authors: Jia Ying; Renee Cattell; Tianyun Zhao; Lan Lei; Zhao Jiang; Shahid M Hussain; Yi Gao; H-H Sherry Chow; Alison T Stopeck; Patricia A Thompson; Chuan Huang Journal: Vis Comput Ind Biomed Art Date: 2022-10-11